Autoplaque vs PMcardio
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is detailed, quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This workstation-based software is ideal for cardiologists and radiologists who require precise measurements and characterization of atherosclerotic plaque to aid in heart attack risk prediction and treatment guidance. It's particularly well-suited for in-depth post-processing of cardiac CT data, allowing for automated segmentation and reviewable measurements of vessel diameter and area.
View Autoplaque →Choose PMcardio if…
Choose PMcardio if you need rapid, AI-powered interpretation of ECGs for the assessment of over 50 cardiac conditions at the point of care. This mobile and web-based platform is excellent for a wide range of healthcare professionals, including those in emergency medicine and primary care, who need quick, expert-level insights to confidently act on critical cardiac events like STEMI or reduced LVEF. Its freemium model and deployment as a mobile app make it highly accessible for immediate diagnostic support and triage in various clinical settings.
View PMcardio →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | PMcardio |
|---|---|---|
| Pricing | Not disclosed | Freemium |
| Deployment | Workstation-based software, runs on Windows or Mac computer platforms | Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems |
| FDA Status | 1 AI-estimated | Pending AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
PMcardioPMcardio offers a mobile app (iOS and Android) and a web platform, making it highly accessible at the point of care for various healthcare professionals. Autoplaque, on the other hand, is workstation-based software, which may limit its flexibility and accessibility in diverse clinical settings. PMcardio's ability to digitize ECGs from images also enhances its usability.
Clinical Value
PMcardioPMcardio is clinically validated in over 25 studies and detects over 50 cardiac conditions from ECGs, including critical conditions like STEMI/OMI and reduced LVEF, with reported improvements in detection sensitivity and reduction in false positives. Autoplaque focuses on quantitative analysis of coronary plaques and luminal stenoses from CT angiography, aiding in heart attack risk prediction, and is FDA-cleared. While both offer significant clinical value, PMcardio's broader scope of detectable conditions from a more readily available diagnostic tool (ECG) and extensive validation give it an edge.
Pricing & Value
PMcardioPMcardio offers a transparent freemium model with a free plan for 5 ECG analyses per month, and a Pro Plan for unlimited use and advanced features. Autoplaque's pricing is not disclosed, making it difficult to assess its value proposition. PMcardio's transparent and flexible pricing, including a free tier, provides greater accessibility and value for individual clinicians and organizations.
Enterprise Readiness
PMcardioPMcardio is designed for enterprise deployment with integrations into EHR/CVIS and EMS systems, offering features like regional data residency, role-based access control, SSO, and full audit trails. It also boasts SOC 2 Type II, ISO 27001, GDPR, and HIPAA compliance. Autoplaque is workstation-based software and its enterprise readiness features like integrations and comprehensive compliance certifications are not specified in the provided information.
Innovation
PMcardioPMcardio demonstrates strong innovation with its AI explainability feature (ECGxplainu2122) providing visual heatmaps for diagnostic rationale, and its ability to detect a wide range of conditions from ECGs, including reduced LVEF. It also has FDA Breakthrough Device Designation for its STEMI AI ECG Model. Autoplaque offers AI-powered quantitative analysis of coronary plaques, which is innovative in its domain, but PMcardio's explainable AI and broader diagnostic capabilities from ECGs suggest a higher degree of innovation in its approach to cardiac diagnostics.
Support & Docs
TiePMcardio provides a Help Center, FAQs, and various legal documents including terms and conditions and privacy notices. Autoplaque's documentation and support offerings are not detailed in the provided information. While PMcardio offers readily available support resources, without comparable information for Autoplaque, a definitive winner cannot be determined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | PMcardio |
|---|---|---|
| Tool Name | Autoplaque | PMcardio |
| Company | Cedars-Sinai Medical Center: AIM | Powerful Medical |
| Description | FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately. |
| Regulatory Clearance | FDA-cleared | CE-certified |
| Key Functionality | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images | Instant AI-powered ECG interpretations; Detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders); Automatic analysis of heart rate, axis, P wave, PR, QRS, and QT/QTc intervals |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and PMcardio.